Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free
  1. Home
  2. Medical News
  3. Diabetes and Endocrinology

Obesity and Diabetes Significantly Increase Risk of Liver Cancer Recurrence, Study Shows

ReachMD Healthcare Image
10/25/2024
News Faviconeurekalert.org

A new study from Osaka Metropolitan University reveals that obesity and diabetes can significantly increase the risk of hepatocellular carcinoma (HCC) relapse after liver resection, underlining the need for managing these conditions in cancer survivors. Hepatocellular carcinoma, a primary type of liver cancer often linked to hepatitis infections, is known for its high rate of recurrence, even after surgical removal. While advances in antiviral therapies have lowered the incidence of HCC, obesity and diabetes are emerging as key factors that complicate long-term survival outcomes.

Researchers, led by Dr. Hiroji Shinkawa, examined 1,644 patients who underwent liver resection for hepatocellular carcinoma to assess how obesity and diabetes influence postoperative cancer recurrence. The results demonstrated that obesity increased the risk of HCC recurrence by approximately 1.5 times within two years post-surgery and by 3.8 times within five years. Diabetes alone was associated with a 1.3 times higher risk of recurrence at two years and a doubling of the risk at five years.

Why It Matters

The findings emphasize the critical role of metabolic health in the management of liver cancer. With obesity and diabetes becoming increasingly prevalent worldwide, their link to higher rates of cancer relapse presents a growing challenge for healthcare professionals. The study suggests that beyond standard cancer treatments, controlling metabolic conditions like obesity and diabetes should be considered a vital part of post-surgical care for HCC patients. By managing these risk factors, healthcare providers may help reduce the likelihood of cancer recurrence and improve long-term outcomes for liver cancer survivors.

Schedule31 Oct 2024